[Ovarian function and recurrence in adjuvant chemotherapy of breast cancer]. 1987

K Schmidt-Gollwitzer, and W Schönegg, and A Scheiber, and J Wessel
Universitäts-Frauenklinik Charlottenburg, Berlin.

The present paper reports the results of a prospective study of the influence of adjuvant chemotherapy (1) on ovarian function and (2) on recurrence and the patient's endocrine function status. Observation criteria were the endocrine status before, during and after chemotherapy. The follow-up period ranged from 12 to 78 months. The patient population comprised 80 women, of whom 39 were treated with AC and 41 with CMF. Of the 80 women, 56 (70.0%) had hypergonadotropic function at the end of treatment; 31 of these had been treated with AC and 25 with CMF. Significantly more women (p less than 0.1) who had undergone AC therapy were hypergonadotropic than among those treated with CMF; 28 of the patients had recurrences during the follow-up period. Among women with undisturbed ovarian function under chemotherapy (eugonadotropinemia), recurrences occurred more frequently (50.0%) than among chemically castrated patients (28.6%). This effect was especially apparent among patients in the AC group with positive receptor status and chemotherapeutically induced ovarian suppression. CMF therapy produced no difference between eugonadotropic and hypergonadotropic patients with regard to frequency of recurrences, not even when there was a correlation with their receptor status.

UI MeSH Term Description Entries
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D010050 Ovarian Function Tests Methods used for assessment of ovarian function. Function Test, Ovarian,Function Tests, Ovarian,Ovarian Function Test,Test, Ovarian Function,Tests, Ovarian Function
D011960 Receptors, Estrogen Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important. Estrogen Receptor,Estrogen Receptors,Estrogen Nuclear Receptor,Estrogen Receptor Type I,Estrogen Receptor Type II,Estrogen Receptors Type I,Estrogen Receptors Type II,Receptor, Estrogen Nuclear,Receptors, Estrogen, Type I,Receptors, Estrogen, Type II,Nuclear Receptor, Estrogen,Receptor, Estrogen
D011980 Receptors, Progesterone Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives. Progesterone Receptors,Progestin Receptor,Progestin Receptors,Receptor, Progesterone,Receptors, Progestin,Progesterone Receptor,Receptor, Progestin
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D005260 Female Females
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU

Related Publications

K Schmidt-Gollwitzer, and W Schönegg, and A Scheiber, and J Wessel
May 1978, Lancet (London, England),
K Schmidt-Gollwitzer, and W Schönegg, and A Scheiber, and J Wessel
June 1987, European journal of cancer & clinical oncology,
K Schmidt-Gollwitzer, and W Schönegg, and A Scheiber, and J Wessel
June 1977, Lancet (London, England),
K Schmidt-Gollwitzer, and W Schönegg, and A Scheiber, and J Wessel
May 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
K Schmidt-Gollwitzer, and W Schönegg, and A Scheiber, and J Wessel
December 1985, Cancer,
K Schmidt-Gollwitzer, and W Schönegg, and A Scheiber, and J Wessel
August 1991, Der Gynakologe,
K Schmidt-Gollwitzer, and W Schönegg, and A Scheiber, and J Wessel
January 2009, The breast journal,
K Schmidt-Gollwitzer, and W Schönegg, and A Scheiber, and J Wessel
March 2015, The New England journal of medicine,
K Schmidt-Gollwitzer, and W Schönegg, and A Scheiber, and J Wessel
January 2019, Journal of Cancer,
K Schmidt-Gollwitzer, and W Schönegg, and A Scheiber, and J Wessel
January 1984, Anticancer research,
Copied contents to your clipboard!